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VENTILATOR-ASSOCIATED PNEUMONIA: 
COMPARING CADAVERIC LIVER TRANSPLANT 
AND NON-TRANSPLANT SURGICAL PATIENTS
Katarina Tomulić Brusich, Ivana Acan and Nataša Višković Filipčić 
Department of Anesthesiology and Intensive Care, Merkur University Hospital, Zagreb, Croatia
SUMMARY – Ventilator-associated pneumonia is a frequent complication in intensive care sur-
gical patients, particularly those with high severity scores on admission. We studied the incidence and 
clinical outcome of ventilator-associated pneumonia among patients undergoing major general sur-
gery procedures and those undergoing cadaveric liver transplantation in our hospital. Patients with the 
intensive care unit stay longer than four days having undergone surgery or transplantation and me-
chanically ventilated for more than 48 hours were included in the study. Ventilator-associated pneu-
monia diagnosis was based on a combination of radiological signs (progressive infi ltrate on chest ra-
diograph), clinical signs (fever >38.3 °C, leukocytes >12×109/mL) and microbiological data (positive 
culture from tracheal aspiration >105 or bronchoalveolar lavage >104 colonies/mL). Medical records of 
1037 patients were reviewed and 157 patients were found to have been mechanically ventilated for 
more than 48 hours: 62 transplanted and 95 non-transplanted. Only 39 (24.84%) patients matched 
the criteria for ventilator-associated pneumonia. Th ere were no diff erences in sex, age, duration of 
mechanical ventilation, length of stay or outcome between the two groups. However, the main diff er-
ence was the mean severity score on admission (Simplifi ed Acute Physiology Score II) which was 
higher among non-transplant patients (42±16 vs. 31±9; p=0.03). Gram-negative bacteria were the 
leading causative agents (82.03%) and were multidrug-resistant. In the intensive care surgical popula-
tion, transplantation per se does not seem to increase patient risk for either ventilator-associated pneu-
monia acquisition or worse outcomes. 
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Introduction
Croatia has over 4.4 million inhabitants. Th ere are 
32 hospitals included in organ donation web and 5 
major transplant centers. Organ donation is defi ned by 
law and donors are reported to the National Trans-
plant Coordinator. Although donation rates have al-
ready increased signifi cantly since 2004, Croatia con-
tinues to improve its organ donation and transplanta-
tion system owing to high level of awareness and con-
tinuous public education. Table 11 shows the number 
of donors, patients on waiting list and liver transplan-
tations performed from 2007 to 2013, which may give 
the reader a better insight into our transplant program. 
Liver transplantation is a widely accepted treat-
ment for patients with end-stage liver disease. A num-
ber of complications can be anticipated after liver 
transplantation, predominantly perioperative surgical 
complications, immune and infectious disorders. De-
spite global improvements in survival over the last few 
decades, sepsis remains the leading cause of early post-
operative mortality and lower respiratory tract infec-
tions also present a major concern. With the advent of 
newer and more potent immunosuppressive regimens, 
graft survival has improved, but at the expense of an 
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increased risk for the development of infections. Nos-
ocomial infections are widely recognized as risk factors 
for prolonged intensive care unit (ICU) stay and mor-
tality. Lungs are the second most common site of in-
fection. A special form of nosocomial pneumonia is 
ventilator associated pneumonia (VAP), developing in 
patients after prolonged (48 hours or more) mechani-
cal ventilation, with the incidence of 8%-28%2. Th e 
development of VAP is associated with several factors 
such as duration of mechanical ventilation, coinci-
dence with chronic obstructive pulmonary disease 
(COPD), sepsis, acute respiratory distress syndrome 
(ARDS), neurologic diseases, trauma and previous an-
tibiotic consumption3,4. 
Transplant patients have a distinct tendency to de-
velop infections, with an emphasis on pneumonia due 
to immunosuppression, alveolar edema after multiple 
blood product transfusions and prolonged postopera-
tive mechanical ventilation due to underlying (multi)
organ failure. Th e incidence of VAP has been shown to 
vary from 5% to 48%, whereas estimates of the related 
mortality rate range from 36.6% to 53%5,6.
Th e aim of this study was to compare the incidence 
of VAP and clinical outcome among patients undergo-
ing liver transplantation (Tx) admitted to our surgical 
ICU with those observed in non-transplanted elective 
surgical patients (non-Tx). 
Patients and Methods
Th is retrospective study was conducted at the Mer-
kur University Hospital, Zagreb, Croatia, a 300-bed 
tertiary care university hospital. It is the leading hospi-
tal in Croatia for solid organ transplantation, namely 
liver and simultaneous pancreas and kidney transplan-
tation. Surgical ICU is a 12-bed unit. 
Th is study was conducted in accordance with the 
amended Declaration of Helsinki. Th e institutional 
 review board (Ethics Committee, No 2013-06/4, July 
18, 2013) approved this study. Th e investigation was 
conducted over a period of 1 year (March 2011 through 
April 2012). 
Perioperative management
Liver allografts were harvested by our senior sur-
geons and were preserved with cold University of Wis-
consin solution. In our center, the piggyback technique 
and preservation of the inferior vena cava is performed 
in all transplants. Venovenous bypass is never used.
For liver transplant patients, there are accurately 
defi ned clinical protocols for perioperative period. 
Preoperative antibiotic prophylaxis in transplant pa-
tients consists of piperacillin + tazobactam, or vanco-
mycin + meropenem in case of allergy to penicillin, 
whereas non-transplant surgical patients receive ce-
fazolin unless they have known allergy to it. 
Liver recipient patients are systematically screened 
preoperatively for methicillin-resistant Staphylococcus 
aureus (MRSA) carriage (nose, throat, armpit and hur-
dle smear). 
All patients receive ulcer prophylaxis with proton 
pump blockers and antithrombotic leg bandage or elas-
tic stockings. Another diff erence is selective digestive 
decontamination (SDD, fl uconazole with garamycin) 
used in transplant patients, which is omitted in surgical 
patients. Non-transplant patients also receive low-mo-
lecular weight heparin the evening before surgery.
Immunosuppressive therapy in transplant patients 
is started intraoperatively by the administration of the 
corticosteroid bolus (methylprednisolone 500 mg) be-
fore graft placing. Upon arrival in the ICU, additional 
Table 1. Total number of deceased donors, patients on waiting list and liver transplantation performed in Croatia 
from 2007 to 2013 (source: www.eurotransplant.org)1
Year 2007 2008 2009 2010 2011 2012 2013
Active liver recipients on waiting list (n) 56 61 54 75 77 73 63
Number of deceased donors (n) 33 79 77 127 144 147 138
Number of liver used (n) 22 66 62 111 125 138 119
Number of liver transplantation 
performed in our hospital (n) 
Liver 22 61 58 99 115 120 110
Right split liver 0 0 0 0 3 1 1
Left split liver 0 0 0 0 2 0 1
Liver + kidney 1 3 1 2 1 2 2
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immunosuppression is gradually introduced with cal-
cineurin inhibitors (cyclosporine or tacrolimus) and 
antimetabolite (mycophenolate mofetil). Prophylaxis 
against cytomegalovirus (CMV) is based on gancyclo-
vir and prophylaxis for Pneumocystis carinii infection 
on sulfamethoxazole + trimethoprim. 
Long-term sedation and, especially, muscle relax-
ation in all patients is avoided in the ICU, except when 
required by the patient’s condition or to perform inva-
sive diagnostic and/or therapeutic procedures. 
In our ICU, fast weaning from mechanical ventila-
tion is encouraged. Extubation is scheduled for early 
postoperative hours after hemodynamic and respiratory 
stability has been achieved. Our weaning protocols are 
physician directed. In this way, they are both fl exible and 
adaptive to the needs of individual patients.
Pneumonia diagnosis 
Patient charts and medical records were reviewed, 
as well as clinical culture isolates within records of the 
clinical microbiology laboratory of our hospital. Infec-
tion was considered to be nosocomial if it appeared 48 
hours after hospital admission and with no evidence of 
pulmonary infection present on admission. All other 
infections were considered community acquired. All 
patients with an ICU stay longer than 4 days who had 
undergone surgery and had been mechanically venti-
lated for over 48 hours were included in the study. 
Subsequently, the patients were divided into two 
groups of liver transplant patients (Tx) and non-trans-
planted elective surgical patients (non-Tx). 
Pneumonia was defi ned as a new infi ltrate on ra-
diological examination together with clinical signs and 
symptoms of infection (temperature >38.3 °C or <36 
°C, leukocyte count >12×109/mL or <4×109/mL, and 
purulent respiratory secretions) and positive microbio-
logical fi ndings. Per protocol in all cases of suspected 
pneumonia, tracheal aspiration or bronchoalveolar la-
vage (BAL) specimens were sent for microbiological 
investigations. Th e diagnostic threshold for BAL 
quantitative culture was 104 colonies/mL and 105 colo-
nies/mL in case of tracheal aspiration. Early-onset 
VAP is defi ned as pneumonia occurring within the 
fi rst 4 days of hospitalization, whereas late-onset VAP 
occurs after this time point. 
Th e patients were compared according to sex, age, 
length of stay in ICU, severity score on admission 
(Simplifi ed Acute Physiology Score II, SAPS II) and 
clinical outcome. 
Pathogens were identifi ed with standard microbio-
logical methods (culture and colony counting meth-
ods). Antibiotic susceptibility was tested with the 
Mueller-Hinton agar diff usion test. Th e production of 
extended-spectrum beta-lactamase was detected by 
the double-disk synergy test. Th e growth of facultative 
pathogenic bacteria such as coagulase-negative Staph-
ylococcus or Candida species was characterized as colo-
nization and did not necessitate therapy. 
Statistical methods 
Statistical analysis was performed using GraphPad 
Software (GraphPad Prism 6, Inc. 2012, La Jolla, CA, 
USA). Normality of distribution was tested with Kol-
mogorov-Smirnov test. Quantitative data were calcu-
lated as mean ± standard deviation (age, SAPS II score, 
ICU length of stay, duration of mechanical ventilation 
and VAP onset); qualitative analysis was reported in 
terms of percentages (sex, VAP incidence, clinical out-
come). Comparison between the two groups was per-
formed by the proportion t-test and c2-test where in-
dicated. A p value ≤0.05 was considered signifi cant. 
Results 
In this 1-year retrospective study, medical records 
and microbiology culture isolates of 1037 patients 
were reviewed. One hundred and fi fty seven patients 
were found to have been mechanically ventilated for 
more than 48 hours, i.e. 62 transplanted (Tx) and 95 
non-transplanted (non-Tx) patients. 
Forty-four patients matched the criteria for VAP 
(28.0%). However, fi ve patients were excluded from 
the study due to their microbiological data which were 
considered to be colonization (Candida albicans and 
coagulase-negative Staphylococcus) and those patients 
did not receive antimicrobial or antifungal therapy. 
Consequently, only 39 patients were treated for VAP 
(24.84%). 
Data collection and valorization is shown in detail 
in Figure 1. Tx-group consisted only of liver recipients 
with an average Model for End Stage Liver Disease 
(MELD) score of 24±5. Non-Tx group consisted 
mostly of patients undergoing cancer surgery in the 
digestive tract (92.85% of gastric, pancreatic and 
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colorectal carcinoma), whereas only 7.14% of patients 
underwent aneurysmatic vascular repair. When look-
ing closely at this subgroup of patients, it is seen that 
the highest incidence of VAP was recorded in patients 
with colorectal cancer (n=12; 46.15%), followed by pa-
tients with pancreatic cancer (n=9; 34.61%) and gastric 
cancer (n=5; 19.23%).
Th e incidence of VAP appeared to be higher among 
non-transplant surgical patients (non-Tx 29.49% vs. 
Tx 17.74%), but not signifi cantly (p=0.5327). Th ere 
was no between-group diff erence according to sex 
(non-Tx male 68.75% vs. Tx male 74.3%), age (non-
Tx 64.44±15 years vs. Tx 56.3±9 years), length of stay 
in the ICU (non-Tx 15.03±15 days vs. Tx 14.92±12 
days) or outcome (non-Tx mortality 40.6% vs. Tx 
mortality 33.3%) (Table 2). However, the main and 
statistically relevant (p<0.05) diff erence was found in 
the mean severity score on admission (SAPS II) which 
was higher among non-transplant patients (non-Tx 
42±16 vs. Tx 31±9; p=0.0303). 
Th ere was no between-group diff erence according 
to the duration of mechanical ventilation either (non-
Tx 8.93±11.65 vs. Tx 7.45±6.79). VAP onset was de-
fi ned as late in both groups; however, earlier occur-
rence was recorded in non-Tx group (non-Tx 6.07±2.67 
vs. Tx 8.18±3.09) (Table 3), which could be correlated 
with SAPS II score. Late VAP occurrence was pre-
dominant, which was consistent with the microbio-
logical data obtained. 
Fig. 1. Study fl ow.
Table 2. Comparison of patients with ventilator-
-associated pneumonia between cadaveric liver 
transplant group (Tx) and non-transplanted major 
surgery patients (non-Tx)
Non-Tx Tx p














Mortality (%) 40.6 33.3 0.0770
ICU = intensive care unit; SAPS II score = Simplifi ed Acute Phy-
siology Score II
Table 3. Duration of mechanical ventilation and onset of 
ventilator-associated pneumonia (VAP) among cadaveric 
liver transplant patients (Tx) and non-transplanted 
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Th e spectrum of causative pathogens was extremely 
diverse (Table 4). Gram-negative bacteria were leading 
in incidence (82.03%) and included multidrug resis-
tant (MDR) bacteria (Acinetobacter baumanii, Pseudo-
monas aeruginosa and extended-spectrum beta-lacta-
mase-producing Escherichia coli, Klebsiella pneumoniae 
and Proteus mirabilis). It is not surprising because of 
the type of surgery (gastroenteral origin of pathogens) 
and due to the late onset of VAP. Gram-positive bacte-
rial VAP had a signifi cantly lower incidence (17.79%). 
Discussion 
Th is study emphasized the importance of VAP 
problem among surgical and cadaveric liver transplant 
populations. We aimed to evaluate, on a retrospective 
basis, the incidence and outcome of VAP and also 
showed the spectrum of causative organisms. Overall, 
we found a VAP incidence of 24.84% and mortality 
rate of 36.1%. Th ese data are comparable to data from 
other centers in Croatia7. In unselected populations of 
mixed ICU patients, the incidence of VAP has been 
reported to be between 5% and 34%8,9, with excessive 
mortality from late-onset VAP, usually over 50%, de-
spite appropriate antibiotic treatment10.
Weiss et al. have reported an incidence rate of 
15.5% specifi cally among liver recipients5. Our rate of 
17.74% among liver recipients agrees with the previ-
ously reported rates of pneumonia after liver trans-
plantation ranging from 5% to 34%. Two recent stud-
ies showed a rate of pneumonia of 21.1% in liver re-
cipients receiving a 3-day prophylactic regimen of ce-
fotaxime and ampicillin and a rate of 18% in living 
donor-related recipients receiving SDD11,12. Interest-
ingly, previous studies have reported rates varying from 
36.6% to 53%13. It suggests an overall improvement in 
the management of severe sepsis or septic shock in 
liver recipients over time, and it might have contrib-
uted to the improvement over time of postoperative 
survival after liver transplantation. 
Liver recipients display a greater risk of respiratory 
tract infections than kidney recipients. One reason is 
the commonly present right sided pleural eff usion in 
the early post transplantation period, which causes at-
electasis6. Another reason is the presence of diaphragm 
dysfunction due to the type of surgery, which is related 
Table 4. Microbiological isolates (tracheal aspiration and/or bronchoalveolar lavage) in patients with 















11 5 16 (41.02%)
Pseudomonas 
aeruginosa
7 3 10 (25.64%)
E. coli (ESBL) 2 1 3 (7.69%)
Klebsiella pneumoniae 
(ESBL)
1 1 2 (5.12%)
Proteus mirabilis 
(ESBL)





6 1 7 (17.97%)




Candida albicans 3 1 4
Tx = liver transplant patients; non-Tx = non-transplanted surgical patients; ESBL= extended-spectrum beta-lactamase-
producing bacteria
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to prolonged mechanical ventilation. From our data, 
we can anticipate that cadaveric liver transplant recipi-
ents and patients undergoing upper abdominal surgery 
have a high incidence of VAP. 
All transplant recipients accumulate other risks 
factors for pneumonia, i.e. immunosuppression and 
underlying end-stage disease with repercussion on 
other organ systems. We also observed the risk of in-
fectious complications to be proportional to the dose 
and number of immunosuppressive medications used. 
Due to the reasons mentioned above, we were rather 
surprised when we found that the incidence of VAP 
was similar in the transplanted and non-transplanted 
patients. Pellegrino et al. also report that liver trans-
plantation does not increase the incidence of VAP 
compared to other surgical patients14. Despite the fact 
that the two groups were comparable in sex, age, length 
of stay in ICU and mortality, the main diff erence was 
found to be SAPS II score on admission to the ICU. A 
high percentage of patients having undergone major 
abdominal surgery due to cancer and patients with 
cardiac comorbidities having undergone major vascu-
lar surgery may explain this fi nding, since they had a 
higher SAPS II score. Th ese fi ndings can explain the 
diff erence between the groups. In fact, age, abdominal 
surgery and neurosurgery are independent risk factors 
for developing VAP in ICU patients15. 
Most of our patients underwent major abdominal 
surgery due to carcinoma. Generally, patients with ma-
lignant disease have diminished immune competence. 
Among less known but clearly important tumor-me-
diated immunosuppressive eff ects is the ability to in-
duce T-cell apoptosis. Th e immune system of cancer 
patients can be compromised through multiple mech-
anisms including immune suppression by the tumor 
and by prior therapies such as chemotherapy and irra-
diation. In a wider point of view, cancer patients can be 
considered as immunosuppressed patients. Th erefore, 
the loss of immune competence may be an important 
risk factor16. Unfortunately, there are no standardized 
tests for immune competence, nor is there agreement 
on what to measure and what is predictive of the out-
come17. 
Daily VAP prevention strategies are performed in 
the ICU, such as mechanical ventilation protocols, se-
dation and weaning protocols, head of bed elevation 
above 30 degrees and oral care with chlorhexidine18. 
However, by examining medical records we found 
several diff erences between the two groups, besides 
immunosuppression. First was the use of SDD in 
transplant patient group, administered prior to anes-
thesia, according to our hospital protocol. In SDD, 
topical antibiotics are applied to the oropharynx and 
stomach for prevention of pneumonia and gut-derived 
infections, in an attempt of possible reduction of infec-
tion-related mortality. 
Despite numerous clinical trials, SDD still remains 
controversial. SDD reduces the incidence of VAP di-
agnoses, but benefi cial eff ects on the duration of venti-
lation or ICU stay, antibiotic use and patient survival 
have not been shown unequivocally. Several recent 
meta-analyses have demonstrated that the use of SDD 
is associated with signifi cant reductions in the inci-
dence of VAP and lower rates of hospital mortality, 
especially among surgical patients19,20. A recent study 
of SDD among surgical patients with a low prevalence 
of colonization with resistant bacteria found a statisti-
cally signifi cant reduction in mortality rate without 
increasing overall colonization with resistant bacte-
ria21. However, like antimicrobial oropharyngeal de-
contamination, SDD carries the potential risk of pro-
moting more widespread antibiotic resistance22. Th ere-
fore, the use of SDD should be carefully monitored for 
the emergence of antimicrobial resistance.
Secondly, all transplanted patients were intubated 
with oropharyngeal tubes with subglottic aspiration 
device, again according to our hospital protocol. Th ese 
tubes were omitted in surgical patients due to the 
 economic policy and due to presumed fast weaning. 
Placement of tubes with subglottic aspiration device is 
considered to be one of the methods of VAP preven-
tion, which does not create a selective growth advan-
tage for resistant microorganisms. Use of this type of 
tubes is an attempt to minimize aspiration of pharyn-
geal secretions. Regular removal of subglottic secre-
tions is thought to reduce the leakage of pharyngeal 
content past the tracheal tube cuff  and into the lower 
respiratory tract. Th e use of these tubes is associated 
with a lower VAP incidence23-25. Th ey are preferentially 
used in all patients suspected of needing oropharyn-
geal intubation for ≥3 days (72 h)26. Th e need of this 
especially exists in liver transplant patients due to un-
derlying encephalopathy, type of surgery, diaphrag-
matic dysfunction and transfusion related overload 
that could lead to prolonged mechanical ventilation. 
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Randomized, controlled studies showed the benefi cial 
eff ect of continuous suctioning of subglottic secretions 
on the incidence of VAP; however, none of the studies 
showed a corresponding eff ect on mortality rate, length 
of stay in ICU or duration of mechanical ventilation27. 
Although neither SDD nor subglottic aspiration 
tubes can individually demonstrate that they have a 
considerable impact on the incidence and mortality of 
VAP, the cumulative eff ect could be dramatic. In addi-
tion to standardized ventilator-weaning protocol de-
signed to reduce time on mechanical ventilation, gas-
trointestinal feeding program that minimizes aspira-
tion and oral-care regimen could markedly reduce 
VAP rate in ICU. 
Many studies have been undertaken in order to 
evaluate prognostic factors in VAP and to improve 
treatment and clinical outcome. Most of them include 
the Clinical Pulmonary Infection Score (CPIS), serum 
procalcitonin and C-reactive protein (CRP) levels 
during the course of VAP28,29. Others include several 
scoring systems (SOFA, APACHE II and SAPS 
II)9,30,31. Th ey are developed in order to ease the assess-
ment of patients, so that physicians are able to accu-
rately and reliably measure the severity of illness in 
ICU. Usually, the ability of a particular score to predict 
mortality is acceptable for a patient group as a whole, 
but this does not apply to predict mortality of the in-
dividual patient. Th e main reason for these shortcom-
ings is the heterogeneity of ICU patient populations. 
Prognostic values of other scoring systems in the 
evaluation of VAP-related mortality have been report-
ed previously in general ICU patients. Studies showed 
that a high SAPS II was one of the three independent 
risk factors for mortality from nosocomial pneumo-
nia32, and also one of the early predictors of infection 
recurrence and death in VAP patients. Leroy et al.33 
and Froon et al.34 showed that SAPS II upon ICU ad-
mission did not diff er signifi cantly between survivors 
and non-survivors, whereas SAPS II determined at 
the onset of VAP was greater in survivors than non-
survivors. Leroy et al.33 also found that SAPS II higher 
than 37 was an independent predictor of the VAP-re-
lated mortality. Our results suggest that it might be 
possible to use this scoring system to predict mortality 
in patients with VAP.
Patients with prolonged ICU stay are prone to be 
colonized and infected by MDR bacteria. In our study, 
the spectrum included many microorganisms, but the 
results were consistent with previous epidemiological 
data. Gram-negative bacteria were leading in inci-
dence (82.03%). Th ey are characterized by resistance to 
many antibiotics and the capability to develop resis-
tance during therapy. In terms of frequency of the 
various pathogens, Acinetobacter baumanii is a particu-
lar problem. Th is is in accordance with microorgan-
isms that occur during late-onset VAP in both surgical 
and non-surgical population. Similar conclusions can 
apply to transplant patients. It should be noted that 
during the study period, there was not an epidemic 
with MDR bacteria, but they rather occurred endemi-
cally. Depuydt et al.35 have reported on 27% of VAP 
patients with MDR pathogens. Th e prevalence of 
MDR pathogens is known to vary depending on the 
patient population and the hospital. Furthermore, 
these patients have often their metabolic and neuro-
hormonal reserves exhausted, while their immune re-
sponse might be severely aff ected. 
Despite the availability of guidelines for the man-
agement of VAP and recent advances in critical care 
medicine, the mortality rate from VAP is still high and 
varies from 24% to 50%11,36. It can even reach 76% 
when the underlying infection is caused by MDR bac-
teria. According to Fagon et al.28, mortality related to 
Pseudomonas or Acinetobacter pneumonia was 87% 
compared to 55% due to any other microorganism iso-
lated pneumonia29. 
Initial antibiotic therapy is a key factor infl uencing 
VAP outcome. Lee et al.32 found that the mortality rate 
was signifi cantly higher in those patients with inap-
propriate initial empirical antibiotic therapy, even 
when subsequent antibiotic therapy was appropriate. 
Early identifi cation of patients at high risk of VAP 
is essential for prevention and treatment, in terms of 
time and initial antibiotic therapy. Knowledge of the 
susceptibility of the local pathogens is necessary for 
choosing appropriate antibiotics. However, the world-
wide emergence of MDR nosocomial gram-negative 
pathogens over the last decade has resulted in the in-
creased use of many forgotten antibiotics. One of those 
is certainly colistin, a polymyxin used as last resort 
therapy for Acinetobacter baumanii isolates, which 
proved to be very eff ective in the treatment of our pa-
tients. 
Th e microbiological ecology may vary greatly 
among ICUs. Consequently, empirical antimicrobial 
therapy guidelines should be tailored according to lo-
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cal epidemiological data. On the other hand, antimi-
crobial consumption has indeed been proven to have 
major infl uence on microbial ecology. Th is also sug-
gests that bacterial multi-resistance might be at least 
partly avoidable even in liver transplant patients. 
Antimicrobial resistance is a growing threat espe-
cially to critically ill patients because treatment failure 
can have serious consequences. To control antimicro-
bial resistance, antimicrobial therapy according to local 
sensitivity result and multidisciplinary management is 
necessary. Th e US Center for Disease Control recom-
mends several steps to prevent antimicrobial resistance 
among hospitalized patients, which includes preven-
tion of infection, early diagnosis and eff ective treat-
ment of infection, using the antimicrobials wisely, and 
prevention of transmission.
Our study had some methodological limitations. 
First, the information was obtained retrospectively 
from charts and medical records review and probably 
was not as complete and accurate as when data collec-
tion is done prospectively. Second, it must be consid-
ered that this was a single center study with a small 
sample size. Despite these limitations, our results pro-
vide important implications for similar demographic 
areas and clinical settings.
However, our study, although retrospective, had 
precise criteria for the diagnosis of VAP, which en-
abled us to draw a reliable picture of VAP in liver re-
cipients, as well as in non-transplanted surgical pa-
tients. Our criteria for clinical suspicion of VAP are 
widely accepted37. Th e period of 4 days was chosen as 
the inclusion period for diagnosis of early VAP onset 
as outlined in the current American Th oracic Society/
Infectious Diseases Society of America guidelines38. 
Despite the small number of patients, we believe 
that these data can be applied to liver transplant pa-
tients in surgical ICU with similar issues and local mi-
crobiological situation. 
In conclusion, this study demonstrated VAP to be 
a common complication in all surgical patients, in-
cluding those after liver transplantation. Th e incidence 
of VAP especially rose among patients with a high se-
verity score on admission to the ICU. SAPS II score 
might be useful in predicting mortality in the popula-
tion of pulmonary patients but additional studies are 
needed on a larger number of patients. Liver trans-
plantation itself did not seem to increase the patient 
risk of either VAP acquisition or worse outcome. Giv-
en the evidence for a greater morbidity and hospital 
mortality rate among VAP patients, the prevention of 
this nosocomial infection should be an important pri-
ority in the hospital setting.
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Sažetak
UPALA PLUĆA UZROKOVANA VENTILATOROM: USPOREDBA BOLESNIKA 
S KADAVERIČNIM PRESATKOM JETRE I KIRURŠKIH BOLESNIKA BEZ PRESATKA 
K. Tomulić Brusich, I. Acan i N. Višković Filipčić 
Upala pluća uzrokovana ventilatorom česta je komplikacija u jedinicama intenzivnog liječenja kirurških bolesnika, naro-
čito onih s visokim stupnjem disfunkcije organa kod prijma. Ispitivala se učestalost i klinički ishod upale pluća uzrokovane 
ventilatorom kod bolesnika podvrgnutih velikim abdominalnim operativnim zahvatima te kod bolesnika nakon kadaverične 
transplantacije jetre. U studiju su bili uključeni bolesnici koji su u Jedinici intenzivnog liječenja boravili duže od četiri dana, 
koji su prošli operaciju ili transplantaciju te koji su bili mehanički ventilirani duže od 48 sati. Dijagnoza se temeljila na kom-
binaciji radioloških znakova (progresija infi ltrata na snimkama prsišta), kliničkih znakova (vrućica >38,3 °C, leukociti 
>12×109/mL) te mikrobioloških podataka (pozitivna kultura aspirata traheje >105 i/ili bronhoalveolarnog lavata >104 kolo-
nije/mL). Pregledani su medicinski zapisi 1037 bolesnika od kojih je njih 157 bilo mehanički ventilirano duže od 48 sati: 62 
transplantiranih i 95 netransplantiranih. Samo 39 (24,84%) bolesnika zadovoljilo je kriterije. Nije nađena razlika u spolu, 
dobi, trajanju mehaničke ventilacije, duljini boravka ili ishodu između ispitivanih skupina. Međutim, glavnu razliku činio je 
bodovni sustav disfunkcije organa kod prijma (Simplifi ed Acute Physiology Score II), koji je bio veći kod netransplantiranih 
bolesnika (42±16 prema 31±9; p=0,03). Multirezistentne gram-negativne bakterije bile su vodeći uzročnik (82,03%). U jedi-
nicama intenzivnog liječenja kirurških bolesnika transplantacija jetre sama po sebi ne povećava rizik za nastanak upale pluća 
uzrokovane ventilatorom kao ni lošiji ishod tih bolesnika.
Ključne riječi: Upala pluća, uzrokovana ventilatorom; Respiracija, umjetna; Jetra, transplantacija; Organska disfunkcija, bodo-
vanje 
